These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 6750405)

  • 21. Depletion of murine CD8+ T cells in vivo decreases pulmonary clearance of a moderately virulent strain of Cryptococcus neoformans.
    Mody CH; Chen GH; Jackson C; Curtis JL; Toews GB
    J Lab Clin Med; 1993 Jun; 121(6):765-73. PubMed ID: 7685044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cryptococcus neoformans: a central nervous system isolate from an AIDS patient that is rhinotropic in a normal mouse model.
    Fromtling RA; Abruzzo GK; Ruiz A
    Mycopathologia; 1988 May; 102(2):79-86. PubMed ID: 3043225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cryptococcus neoformans. I. Nonencapsulated mutants.
    Bulmer GS; Sans MD; Gunn CM
    J Bacteriol; 1967 Nov; 94(5):1475-9. PubMed ID: 6057803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Th1-Th2 cytokine kinetics in the bronchoalveolar lavage fluid of mice infected with Cryptococcus neoformans of different virulences.
    Abe K; Kadota J; Ishimatsu Y; Iwashita T; Tomono K; Kawakami K; Kohno S
    Microbiol Immunol; 2000; 44(10):849-55. PubMed ID: 11128069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virulence of Cryptococcus neoformans serotypes A, B, C and D for four mouse strains.
    Irokanulo EA; Akueshi CO
    J Med Microbiol; 1995 Oct; 43(4):289-93. PubMed ID: 7562991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide.
    Granger DL; Perfect JR; Durack DT
    J Clin Invest; 1985 Aug; 76(2):508-16. PubMed ID: 3928681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parallel beta-helix proteins required for accurate capsule polysaccharide synthesis and virulence in the yeast Cryptococcus neoformans.
    Liu OW; Kelly MJ; Chow ED; Madhani HD
    Eukaryot Cell; 2007 Apr; 6(4):630-40. PubMed ID: 17337638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.
    Rachini A; Pietrella D; Lupo P; Torosantucci A; Chiani P; Bromuro C; Proietti C; Bistoni F; Cassone A; Vecchiarelli A
    Infect Immun; 2007 Nov; 75(11):5085-94. PubMed ID: 17606600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective involvement of the brain in experimental murine cryptococcosis. II. Histopathological observations.
    Grosse G; Mishra SK; Staib F
    Zentralbl Bakteriol Orig A; 1975 Sep; 233(1):106-22. PubMed ID: 1106066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variants of a Cryptococcus neoformans strain elicit different inflammatory responses in mice.
    Chen LC; Casadevall A
    Clin Diagn Lab Immunol; 1999 Mar; 6(2):266-8. PubMed ID: 10066665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characterization and evaluation of virulence factors of Cryptococcus laurentii and Cryptococcus neoformans strains isolated from external hospital areas.
    Andrade-Silva L; Ferreira-Paim K; Silva-Vergara ML; Pedrosa AL
    Fungal Biol; 2010; 114(5-6):438-45. PubMed ID: 20943154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment of protective immunity against cerebral cryptococcosis by means of an avirulent, non melanogenic Cryptococcus neoformans strain.
    Barluzzi R; Brozzetti A; Mariucci G; Tantucci M; Neglia RG; Bistoni F; Blasi E
    J Neuroimmunol; 2000 Sep; 109(2):75-86. PubMed ID: 10996209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cryptococcus neoformans--pathogen and saprophyte.
    Campbell CK; Mackenzie DW
    Soc Appl Bacteriol Symp Ser; 1980; 9():249-58. PubMed ID: 7013081
    [No Abstract]   [Full Text] [Related]  

  • 34. Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro: role of the capsule.
    Ibrahim AS; Filler SG; Alcouloumre MS; Kozel TR; Edwards JE; Ghannoum MA
    Infect Immun; 1995 Nov; 63(11):4368-74. PubMed ID: 7591072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans.
    Sanguinetti M; Posteraro B; La Sorda M; Torelli R; Fiori B; Santangelo R; Delogu G; Fadda G
    Infect Immun; 2006 Feb; 74(2):1352-9. PubMed ID: 16428784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility of congenitally immunodeficient mice to a nonencapsulated strain of Cryptococcus neoformans.
    Salkowski CA; Balish E
    Can J Microbiol; 1991 Nov; 37(11):834-9. PubMed ID: 1777860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans.
    Mody CH; Syme RM
    Infect Immun; 1993 Feb; 61(2):464-9. PubMed ID: 8423074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization of mice with a mutant of Cryptococcus neoformans. Characterization of the mutant, actively acquired resistance to experimental cryptococcosis in mice.
    Reiss F; Alture-Werber E
    Dermatologica; 1976; 152(1):16-22. PubMed ID: 780165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of CTR4 deletion on virulence and stress response in Cryptococcus neoformans.
    Zhang P; Zhang D; Zhao X; Wei D; Wang Y; Zhu X
    Antonie Van Leeuwenhoek; 2016 Aug; 109(8):1081-90. PubMed ID: 27317510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Selective infection of the central nervous system by Cryptococcus neoformans--animal studies with the use of special bacterial strains].
    Grosse G; Staib F; Mishra SK; Abel T
    Verh Dtsch Ges Pathol; 1978; 62():347. PubMed ID: 371214
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.